About Yili Chuanning
Yili Chuanning Biotechnology, headquartered in Shanghai’s Xuhui District at the Yanxiang Science Building, leads China’s biotechnology research and development sector. Operating from the Horgos Economic Development Zone, the company maintains:
- 16,000 tons annual production capacity of pharmaceutical intermediates
- 68 authorized patents and multiple engineering centers
- 2.7 billion yuan investment in environmental protection
- State-of-the-art fermentation facilities
With its recent IPO raising 1.114 billion yuan and strategic presence in both Shanghai and Xinjiang, Yili Chuanning advances sustainable pharmaceutical manufacturing across China.
Frequently asked questions
Yili Chuanning Biotechnology manufactures these pharmaceutical products:
- Antibiotics
- Thiocyanate erythromycin
- Cephalosporin intermediates
- Penicillin intermediates
- APIs
- UDCA (Ursodeoxycholic Acid)
Annual production capacity: 16,000 tons
Raw material processing:
- 450,000 tons of corn
- 200,000 tons of soybean meal
- 1.2 million tons of coal
The company maintains these technical assets:
| Category | Details |
|---|---|
| Research Facilities |
|
| Intellectual Property |
|
| Environmental Systems |
|
The company operates in the following location:
Manufacturing FacilityHorgos Economic Development Zone
Yining Industrial Park
Xinjiang, China
Facility specifications:
- Plant area
- Total area: 1,304 mu
- Environmental systems: 300 mu
- Production facilities
- Fermentation units
- Processing plants
- Environmental protection systems
More details about Yili Chuanning
A leading biotechnology company in Shanghai
Yili Chuanning Biotechnology, established in 2010, operates from the Yanxiang Science and Technology Building in Shanghai’s Xuhui District. The company has grown into a major player in China’s biotechnology sector, with facilities in the Horgos Economic Development Zone.
Advanced research and production capabilities
As a cosmetic lab and pharmaceutical manufacturer, Yili Chuanning Biotechnology maintains an annual production capacity of 16,000 tons. The company specializes in producing thiocyanate erythromycin, cephalosporin, penicillin intermediates, and UDCA API.
Innovation and research excellence
The company’s commitment to advancement is demonstrated through its research infrastructure, including a national-level innovation platform and three regional engineering technology centers. With 68 authorized patents, including 32 invention patents, Yili Chuanning leads in industrial innovation.
Environmental commitment and sustainable practices
Operating from Shanghai, the company has invested 2.7 billion yuan in environmental protection facilities. This investment represents 34% of total project funding, highlighting their dedication to green manufacturing practices in China’s biotechnology sector.
Production scale and resources
The facility processes significant quantities of raw materials annually:
- 1.2 million tons of coal
- 450,000 tons of corn
- 200,000 tons of soybean meal
Market position and growth
Following its successful IPO in December 2022, Yili Chuanning Biotechnology (stock code 301301) raised 1.114 billion yuan, strengthening its position in Shanghai’s competitive biotechnology market. The company continues to expand its operations while maintaining high standards in research and production.
Company gallery
